Accelerating clinical evaluation
Nidek Technologies, manufacturers of ophthalmological devices, knows the key to verifying manufacturability is accurate prototypes. But the multiple iterations usually necessary for success are costly and time-consuming to produce.
“The ability to validate designs early in the product development cycle helps us eliminate costly iterations during manufacturing, as well as significantly reducing our time-to-market compared to traditional prototyping methods,” said Cesare Tanassi, CEO at Nidek.
3D printing also proved critical for the development stage of clinical trials. “For the Gonioscope, the quality of the 3D printed components helped the device pass a year-long clinical trial where eight global medical centers examined it. This device will soon be utilized by clinics and hospitals around the globe, contributing to a novel way to diagnose glaucoma,” said Tanassi
Nidek Streamlines Prototyping
3D Printing vs. CNC
75% Less Cost
50% Faster Time-to-Market
|
80%
of Syqe’s clinical trial device was 3D printed.
Syqe first tried creating its novel inhaler for clinical trials using traditional CNC machining. But frequent iteration became costly. “One of the biggest design challenges was the inhalation system. Different patients inhale in different ways, different age groups have different lung volumes. We needed to create an airflow system that is completely patient-agnostic,” said Perry Davidson, Syqe founder and CEO.
Ultimately, Syqe’s successful clinical trial used a device that was 80% 3D printed. Its final product also contains many 3D printed parts, even ones that come into contact with the human body. For example, the inhalation mechanism is 3D printed using Stratasys MED610™, a biocompatible material.